CA2213343A1 - Chimeric adenoviral fiber protein and methods of using same - Google Patents

Chimeric adenoviral fiber protein and methods of using same

Info

Publication number
CA2213343A1
CA2213343A1 CA002213343A CA2213343A CA2213343A1 CA 2213343 A1 CA2213343 A1 CA 2213343A1 CA 002213343 A CA002213343 A CA 002213343A CA 2213343 A CA2213343 A CA 2213343A CA 2213343 A1 CA2213343 A1 CA 2213343A1
Authority
CA
Canada
Prior art keywords
methods
fiber protein
same
adenoviral fiber
chimeric adenoviral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002213343A
Other languages
French (fr)
Other versions
CA2213343C (en
Inventor
Thomas J. Wickham
Erik Falck-Pedersen
Petrus W. Roelvink
Joseph T. Bruder
Jason Gall
Imre Kovesdi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell Research Foundation Inc
Genvec Inc
Original Assignee
Genvec, Inc.
Thomas J. Wickham
Erik Falck-Pedersen
Petrus W. Roelvink
Joseph T. Bruder
Jason Gall
Imre Kovesdi
Cornell Research Foundation, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genvec, Inc., Thomas J. Wickham, Erik Falck-Pedersen, Petrus W. Roelvink, Joseph T. Bruder, Jason Gall, Imre Kovesdi, Cornell Research Foundation, Inc. filed Critical Genvec, Inc.
Publication of CA2213343A1 publication Critical patent/CA2213343A1/en
Application granted granted Critical
Publication of CA2213343C publication Critical patent/CA2213343C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405—Vectors comprising RGD peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Abstract

A recombinant adenovirus comprising a chimeric fiber protein and a therapeutic gene, a method of gene therapy involving the use of such an adenovirus, and an adenoviral transfer vector for the generation of such a recombinant adenovirus are provided.
CA002213343A 1995-02-21 1996-02-13 Chimeric adenoviral fiber protein and methods of using same Expired - Fee Related CA2213343C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/395,381 1995-02-21
US08/395,381 US5770442A (en) 1995-02-21 1995-02-21 Chimeric adenoviral fiber protein and methods of using same
PCT/US1996/001957 WO1996026281A1 (en) 1995-02-21 1996-02-13 Chimeric adenoviral fiber protein and methods of using same

Publications (2)

Publication Number Publication Date
CA2213343A1 true CA2213343A1 (en) 1996-08-29
CA2213343C CA2213343C (en) 2009-09-01

Family

ID=23562798

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002213343A Expired - Fee Related CA2213343C (en) 1995-02-21 1996-02-13 Chimeric adenoviral fiber protein and methods of using same

Country Status (8)

Country Link
US (3) US5770442A (en)
EP (1) EP0811069B1 (en)
JP (1) JPH11500315A (en)
AT (1) ATE397075T1 (en)
AU (1) AU698254B2 (en)
CA (1) CA2213343C (en)
DE (1) DE69637545D1 (en)
WO (1) WO1996026281A1 (en)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820868A (en) 1993-12-09 1998-10-13 Veterinary Infectious Disease Organization Recombinant protein production in bovine adenovirus expression vector system
US6465253B1 (en) * 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5998205A (en) * 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
DK1445322T4 (en) * 1995-06-15 2012-09-03 Crucell Holland Bv Packaging systems for human recombinant adenovirus for use in gene therapy
US20020068049A1 (en) * 1998-09-10 2002-06-06 Henderson Daniel R. Tissue specific adenoviral vectors
WO1997012048A1 (en) * 1995-09-27 1997-04-03 Medical Research Council Recombinant viruses incorporating a protease cleavable protein
BR9612685A (en) * 1995-11-28 1999-07-20 Genvec Inc Vectors and methods for gene transfer to cells
AU742018B2 (en) * 1996-08-21 2001-12-13 Genvec, Inc. Alternatively targeted adenovirus
US6420629B1 (en) * 1996-09-09 2002-07-16 B.C. Research Inc. Process of increasing plant growth and yield and modifying cellulose production in plants
ATE420182T1 (en) * 1996-09-25 2009-01-15 Scripps Research Inst PACKAGING CELL LINES USED TO FACILITATE THE DEVELOPMENT OF HIGHLY EFFICIENT ADENOVIRAL VECTORS
US7232899B2 (en) * 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
WO1998017322A1 (en) * 1996-10-24 1998-04-30 Genzyme Corporation And President And Fellows Of Harvard College Enhanced delivery of adenoviral vectors to lung tissue
US5877011A (en) * 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
AU6442998A (en) * 1997-03-14 1998-10-12 Uab Research Foundation Method for the purification of virus
US6432699B1 (en) * 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
FR2761688A1 (en) * 1997-04-02 1998-10-09 Transgene Sa New adenovirus with mutations in the fibre protein to alter binding selectivity
FR2761689B1 (en) * 1997-04-02 1999-06-25 Transgene Sa MODIFIED ADENOVIRAL FIBER AND TARGET ADENOVIRUS
CA2289215A1 (en) * 1997-05-08 1998-11-12 Genetic Therapy, Inc. Gene transfer with adenoviruses having modified fiber proteins
JP2001518806A (en) * 1997-05-28 2001-10-16 ジェンベク、インコーポレイティッド Alternately targeted adenovirus
CA2294649C (en) 1997-06-23 2007-09-25 University Of Saskatchewan Bovine adenovirus type 3 genome
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US20030045492A1 (en) * 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US6706693B1 (en) 1997-08-13 2004-03-16 The Uab Research Foundation Vaccination by topical application of genetic vectors
US20030125278A1 (en) * 1997-08-13 2003-07-03 Tang De-Chu C. Immunization of animals by topical applications of a salmonella-based vector
US6348450B1 (en) * 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
US7297542B2 (en) * 1998-02-06 2007-11-20 The Uab Research Foundation Adenovirus vector containing a heterologous peptide epitope in the hi loop of the fiber knob
US20050095231A1 (en) * 1998-02-17 2005-05-05 Curiel David T. Modified adenovirus containing a fiber replacement protein
US6815200B1 (en) 1998-02-17 2004-11-09 The Uab Research Foundation Modified adenovirus containing a fiber replacement protein
US6210946B1 (en) * 1998-02-17 2001-04-03 Uab Research Foundation Modified adenovirus containing a fiber replacement protein
US6670188B1 (en) * 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
AU4070499A (en) 1998-04-30 1999-11-16 Cornell Research Foundation Inc. Adenoviral vectors with tandem fiber proteins
AU2003268608B2 (en) * 1998-07-08 2007-01-04 Crucell Holland B.V. Chimaeric adenoviruses
US20030017138A1 (en) * 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US20040043489A1 (en) * 1998-07-08 2004-03-04 Menzo Havenga Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
EP1108047A1 (en) 1998-08-27 2001-06-20 Aventis Pharma S.A. Targeted adenovirus vectors for delivery of heterologous genes
US6900049B2 (en) * 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US6455314B1 (en) 1998-09-11 2002-09-24 Genvec, Inc. Alternatively targeted adenovirus
US6929946B1 (en) * 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
IL133032A (en) * 1998-11-20 2007-06-03 Introgene Bv Adenoviral gene delivery vectors provided with a tissue tropism for smooth muscle cells and /or endothelial cells
DE60039683D1 (en) * 1999-03-04 2008-09-11 Crucell Holland Bv USE OF AN ADENOVIRUS VECTOR FOR THE TRANSDUCTION OF SYNOVIAL CELLS
US6869936B1 (en) * 1999-03-04 2005-03-22 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
WO2000067576A1 (en) * 1999-05-12 2000-11-16 The Uab Research Foundation Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
US20050232900A1 (en) * 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6913922B1 (en) * 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) * 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
JP2003531568A (en) * 1999-07-06 2003-10-28 ゴット−エー−ジェーン・エービー Recombinant adenovirus
EP1124977A1 (en) 1999-08-27 2001-08-22 Transgene S.A. Modified adenoviral fibre and uses thereof
CA2385538C (en) * 1999-09-17 2007-11-06 Tgt Laboratories, S.A. De C.V. Recombinant adenoviral vectors and their utilization in the treatment of various types of hepatic, renal and pulmonary fibrosis and hypertrophic scars
EP1276888A2 (en) * 2000-04-26 2003-01-22 Crucell Holland B.V. Adenovirus vectors with knobless fibers, and their uses
EP1157999A1 (en) * 2000-05-24 2001-11-28 Introgene B.V. Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof
EP1301612A2 (en) * 2000-05-31 2003-04-16 Genvec, Inc. Method and composition for targeting an adenoviral vector
US6524572B1 (en) * 2000-06-26 2003-02-25 Rainbow Therapeutic Company Targeting recombinant virus with a bispecific fusion protein ligand in coupling with an antibody to cells for gene therapy
US20020164333A1 (en) * 2000-07-10 2002-11-07 The Scripps Research Institute Bifunctional molecules and vectors complexed therewith for targeted gene delivery
NZ524743A (en) * 2000-09-20 2004-07-30 Crucell Holland B Gene delivery vectors provided with a tissue tropism for dendritic cells provided by a viral capsid protein
US7235233B2 (en) * 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
US20030202963A1 (en) * 2000-10-12 2003-10-30 Cornell Research Foundation, Inc. Method of treating cancer
MXPA00011713A (en) * 2000-11-28 2002-05-31 Tgt Lab S A De C V Re-combining viral and non-viral vectors containing the human gene of the urokinase plasminogen activator and its benefit in the treatment of diverse types of hepatic, renal, pulmonary, pancreatic and cardiac fibrosis and hypertrophic scars.
WO2003046124A2 (en) 2001-11-21 2003-06-05 The Trustees Of The University Of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
US7344872B2 (en) 2001-06-22 2008-03-18 The Trustees Of The University Of Pennsylvania Method for rapid screening of bacterial transformants and novel simian adenovirus proteins
US20060275262A1 (en) * 2001-07-26 2006-12-07 Mathis James M Conditionally replicating viruses and methods for cancer virotherapy
US9175309B2 (en) * 2001-09-29 2015-11-03 Industry-University Cooperation Foundation Hanyang University Recombinant adenovirus with enhanced therapeutic effect and pharmaceutical composition comprising said recombinant adenovirus
US7175983B2 (en) * 2001-11-02 2007-02-13 Abmaxis, Inc. Adapter-directed display systems
AU2006204656B2 (en) * 2001-11-21 2008-01-24 The Trustees Of The University Of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
JP4488290B2 (en) * 2002-01-24 2010-06-23 ザ・スクリップス・リサーチ・インスティテュート Fiber shaft mutation for efficient targeting
IL164802A0 (en) 2002-04-25 2005-12-18 Crucell Holland Bv Stable adenoviral vectors and methods for propagation thereof
SI1497438T1 (en) * 2002-04-25 2010-03-31 Crucell Holland Bv Means and methods for the production of adenovirus vectors
WO2003092594A2 (en) * 2002-04-30 2003-11-13 Duke University Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
EP1523563A2 (en) * 2002-07-10 2005-04-20 Transgene S.A. Modified adenoviral fiber with ablated to cellular receptors
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
EP1553983A2 (en) 2002-10-23 2005-07-20 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
EP2258850B1 (en) 2002-12-17 2013-07-17 Crucell Holland B.V. Recominant viral-based malaria vaccins
ATE521701T1 (en) 2003-01-22 2011-09-15 Univ Duke IMPROVED CONSTRUCTS FOR EXPRESSING LYSOSOMAL POLYPEPTIDES
US20040166091A1 (en) 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
WO2004101799A2 (en) 2003-05-14 2004-11-25 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Broadening adenovirus tropism
US7498024B2 (en) * 2003-06-03 2009-03-03 Cell Genesys, Inc. Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage site
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
US7291498B2 (en) * 2003-06-20 2007-11-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
WO2005001103A2 (en) * 2003-06-20 2005-01-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
EP1649028B1 (en) * 2003-07-25 2012-08-22 Genvec, Inc. Adenoviral vector-based vaccines
US20050186178A1 (en) * 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
US7482156B2 (en) * 2003-10-15 2009-01-27 Cell Genesys, Inc. Hepatocellular carcinoma specific promoter and uses thereof
EP1687032B1 (en) * 2003-11-14 2010-02-24 Genvec, Inc. Pharmaceutical composition for treating unresectable, locally advanced pancreatic cancer (lapc).
ES2329607T3 (en) 2004-02-23 2009-11-27 Crucell Holland B.V. VIRUS PURIFICATION METHODS
US20070207166A1 (en) 2004-04-12 2007-09-06 Genvec, Inc. Method of Using Adenoviral Vectors to Induce an Immune Response
US20060062764A1 (en) * 2004-08-25 2006-03-23 Seshidar-Reddy Police Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
WO2006039045A2 (en) * 2004-09-01 2006-04-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenoviral vectors able to transduce apcs, potential use in immune response generation
KR20070120970A (en) * 2005-02-23 2007-12-26 유에이비 리서치 파운데이션 Alkyl-glycoside enhanced vaccination
US20060205080A1 (en) * 2005-03-01 2006-09-14 David Frey Formulations for therapeutic viruses having enhanced storage stability
US20070010016A1 (en) * 2005-03-11 2007-01-11 Mccelland Alan Gene transfer with adenoviruses having modified fiber proteins
CA2602944C (en) 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
US9651543B2 (en) 2005-08-31 2017-05-16 The United States Of America As Represented By The Secretary Of The Navy Malaria antigen screening method
US8450055B2 (en) * 2005-08-31 2013-05-28 The United States Of America As Represented By The Secretary Of The Navy Malaria antigen screening method
AU2006284756B2 (en) * 2005-08-31 2012-06-07 Genvec, Inc. Adenoviral vector-based malaria vaccines
EP1951297A2 (en) * 2005-11-10 2008-08-06 GenVec, Inc. Adenoviral vector-based foot-and-mouth disease vaccine
CA2646671A1 (en) 2006-03-30 2007-11-01 University Of California Methods and compositions for localized secretion of anti-ctla-4 antibodies
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
CA2675022A1 (en) * 2007-01-09 2008-07-17 Genvec, Inc. Adenoviral vector-based malaria vaccines
US8629334B2 (en) * 2008-07-16 2014-01-14 University Of Florida Research Foundation, Inc. Viral-based transient-expression vector system for trees
CA2742474C (en) 2008-11-03 2016-05-31 Crucell Holland B.V. Method for the production of adenoviral vectors
US9605844B2 (en) * 2009-09-01 2017-03-28 Cree, Inc. Lighting device with heat dissipation elements
BR112012008507B8 (en) 2009-10-15 2021-05-25 Crucell Holland Bv method for purifying adenovirus particles from a cell suspension
EA028623B1 (en) 2009-10-15 2017-12-29 Янссен Вэксинс Энд Превеншн Б.В. Method for the purification of adenovirus particles
WO2011047316A1 (en) 2009-10-16 2011-04-21 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Nucleic acid sequences encoding expandable hiv mosaic proteins
WO2011057254A2 (en) 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Simian adenoviral vector-based vaccines
WO2011057248A2 (en) 2009-11-09 2011-05-12 Genvec, Inc. Simian adenovirus and methods of use
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
CA2808556A1 (en) 2010-09-20 2012-03-29 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
US9512429B2 (en) 2010-12-06 2016-12-06 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Pharmaceutical composition comprising Nanog shRNA, and method of using Nanog shRNA to treat cancer
WO2012083297A2 (en) 2010-12-17 2012-06-21 Genvec, Inc. Adenoviral vectors with modified hexon regions
EP2654786B1 (en) 2010-12-20 2019-02-20 GenVec, Inc. Adenoviral vector-based dengue fever vaccine
US9790519B2 (en) 2012-05-29 2017-10-17 Genvec, Inc. Modified serotype 28 adenoviral vectors
CA3115891A1 (en) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions
JP6576904B2 (en) 2013-04-04 2019-09-18 トラスティーズ・オブ・ダートマス・カレッジ Compositions and methods for in vivo excision of HIV-1 proviral DNA
KR102258348B1 (en) 2013-09-19 2021-05-31 얀센 백신스 앤드 프리벤션 비.브이. Improved adenovirus formulations
TWI710635B (en) 2014-10-09 2020-11-21 美商珍維克公司 Adenoviral vector encoding human atonal homolog-1 (hath1)
WO2017060329A1 (en) 2015-10-06 2017-04-13 Janssen Vaccines & Prevention B.V. Methods for preventing plastic-induced degradation of biologicals
WO2017070113A1 (en) 2015-10-19 2017-04-27 The United States of America, as represented by the Secretary, Department of Health and Human Sevices Pharmaceutical composition comprising nanog shrna, and method of using nanog shrna to treat cancer
CN108699566B (en) 2016-02-23 2023-06-30 萨克生物研究学院 Treatment of exogenous gene expression in adenoviruses with minimal effect on viral kinetics
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
WO2018064523A1 (en) 2016-09-30 2018-04-05 Genvec, Inc. Adenovectors for delivery of therapeutic genetic material into t cells
CN110062630A (en) 2016-12-12 2019-07-26 萨克生物研究学院 Cancer target synthesizes adenovirus and application thereof
US11542526B2 (en) 2019-02-21 2023-01-03 Unleash Immuno Oncolytics, Inc. Oncolytic adenoviral vector and methods of use
EP4338727A1 (en) 2022-09-14 2024-03-20 Roquette Freres Adenovirus formulations

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593002A (en) * 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
US4487829A (en) * 1982-03-23 1984-12-11 Massachusetts Institute Of Technology Production and use of monoclonal antibodies against adenoviruses
US4589881A (en) * 1982-08-04 1986-05-20 La Jolla Cancer Research Foundation Polypeptide
US4792525A (en) * 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
US4517686A (en) * 1982-08-04 1985-05-21 La Jolla Cancer Research Foundation Polypeptide
US4578079A (en) * 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
FR2602790B1 (en) * 1986-08-13 1990-06-01 Transgene Sa EXPRESSION OF A SPECIFIC TUMOR ANTIGEN BY A RECOMBINANT VECTOR VIRUS AND USE THEREOF FOR THE PREVENTIVE OR CURATIVE TREATMENT OF THE CORRESPONDING TUMOR
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US4956281A (en) * 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
US5024939A (en) * 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
US5674722A (en) * 1987-12-11 1997-10-07 Somatix Therapy Corporation Genetic modification of endothelial cells
US5672344A (en) * 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA2000048A1 (en) * 1988-10-03 1990-04-03 Edward F. Plow Peptides and antibodies that inhibit integrin-ligand bindin g
US5096815A (en) * 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) * 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
EP0466815A4 (en) 1989-04-05 1992-09-02 Novacell Corpporation Infectious targetted replication-defective virion
US5223394A (en) * 1989-04-10 1993-06-29 Biogen, Inc. Recombinant dna molecule comprising lymphocyte function-associated antigen 3 phosphatidylinositol linkage signal sequence
DK0479909T3 (en) * 1989-06-29 1997-04-07 Medarex Inc Bispecific reagents for AIDS treatment
US5240846A (en) * 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5332567A (en) * 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
US5436146A (en) * 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
ES2133139T3 (en) * 1989-10-20 1999-09-01 Medarex Inc BISPECIFIC ANTIBODIES HETERO WITH DOUBLE EFFECTIVE FUNCTIONS.
EP0496818B1 (en) * 1989-10-20 1999-06-23 Trustees Of Dartmouth College MONOCLONAL ANTIBODY SPECIFIC FOR IgA RECEPTOR
WO1991018088A1 (en) * 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US5246921A (en) * 1990-06-26 1993-09-21 The Wistar Institute Of Anatomy And Biology Method for treating leukemias
GB2246779B (en) * 1990-08-03 1994-08-17 Delta Biotechnology Ltd Tumour-associated protease inhibitors targeted to tumour cells
CA2092323A1 (en) 1990-10-01 1992-04-02 George Y. Wu Targeting viruses and cells for selective internalization by cells
GB9101550D0 (en) * 1991-01-24 1991-03-06 Mastico Robert A Antigen-presenting chimaeric protein
WO1993003769A1 (en) * 1991-08-20 1993-03-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Adenovirus mediated transfer of genes to the gastrointestinal tract
FR2681786A1 (en) * 1991-09-27 1993-04-02 Centre Nat Rech Scient RECOMBINANT VECTORS OF VIRAL ORIGIN, PROCESS FOR OBTAINING SAME AND THEIR USE FOR THE EXPRESSION OF POLYPEPTIDES IN MUSCLE CELLS.
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
IL103059A0 (en) * 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
SE503225C2 (en) 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antibody complex for introduction of virus into mammalian cells
US5661133B1 (en) * 1991-11-12 1999-06-01 Univ Michigan Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein
JPH07507689A (en) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Specific tissue targeting methods and compositions
US5723287A (en) 1992-09-22 1998-03-03 Medical Research Council Recombinant viruses displaying a nonviral polypeptide on their external surface
EP0669987B1 (en) * 1992-09-25 2008-08-13 Aventis Pharma S.A. Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
DE4232846A1 (en) * 1992-09-30 1994-03-31 Audi Ag Cross member for the dashboard of a motor vehicle
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
WO1994011506A1 (en) * 1992-11-18 1994-05-26 Arch Development Corporation Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle
GB9300686D0 (en) 1993-01-15 1993-03-03 Imp Cancer Res Tech Compounds for targeting
WO1994017832A1 (en) * 1993-02-09 1994-08-18 The Scripps Research Institute Targeting and delivery of genes and antiviral agents into cells by the adenovirus penton
DE4311651A1 (en) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus for the transport of foreign DNA into higher eukaryotic cells
EP0698109B1 (en) * 1993-05-10 2002-07-31 The Regents Of The University Of Michigan Gene transfer into pancreatic epithelial cells
US5543328A (en) 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
WO1995006745A1 (en) * 1993-09-03 1995-03-09 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Vector for gene therapy of the liver
US5552311A (en) * 1993-09-14 1996-09-03 University Of Alabama At Birmingham Research Foundation Purine nucleoside phosphorylase gene therapy for human malignancy
US5534423A (en) * 1993-10-08 1996-07-09 Regents Of The University Of Michigan Methods of increasing rates of infection by directing motion of vectors
FR2712812B1 (en) * 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition for the production of therapeutic products in vivo.
IT1271461B (en) * 1993-12-01 1997-05-28 Menarini Ricerche Sud Spa ANTI-CD3 / ANTI-EGFR MONOCLONAL ANTI-BODY ANTIBODY, PROCESS FOR PRODUCTION AND ITS USE.
US5491565A (en) * 1993-12-03 1996-02-13 Telefonaktiebolaget Lm Ericsson System and method for varying the transmission rate of facsimile data in a telecommunication system
US5443953A (en) * 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
US5928944A (en) * 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
US6312699B1 (en) * 1994-03-28 2001-11-06 Uab Research Foundation Ligands added to adenovirus fiber
US7252989B1 (en) * 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
AU2589695A (en) * 1994-05-13 1995-12-05 Chiron Corporation Compositions and methods for targeting gene delivery vehicles
US5571531A (en) * 1994-05-18 1996-11-05 Mcmaster University Microparticle delivery system with a functionalized silicone bonded to the matrix
FR2721943B1 (en) * 1994-06-29 1996-08-02 Rhone Poulenc Rorer Sa ADENOVIRUS COMPRISING A GENE ENCODING A SUPEROXIDE DISMUTASE
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
EP0779923A2 (en) * 1994-09-09 1997-06-25 Neurocrine Biosciences, Inc. Interleukin-1 type 3 receptors
FR2724846B1 (en) * 1994-09-27 1996-12-20 Rhone Poulenc Rorer Sa METHOD OF TREATING CANCER BY REGULATING THE ACTIVITY OF RAS PROTEINS
DK0787200T3 (en) * 1994-10-28 2005-08-15 Univ Pennsylvania Improved adenovirus and methods for its use
WO1996014837A1 (en) * 1994-11-09 1996-05-23 Genetic Therapy, Inc. Gene therapy for hypercholesterolemia
JP3351471B2 (en) * 1994-11-29 2002-11-25 タカラバイオ株式会社 Method for producing transformed cells
FR2727867B1 (en) * 1994-12-13 1997-01-31 Rhone Poulenc Rorer Sa GENE TRANSFER IN MEDULLAR MOTONURONES USING ADENOVIRAL VECTORS
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6127525A (en) 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5622699A (en) 1995-09-11 1997-04-22 La Jolla Cancer Research Foundation Method of identifying molecules that home to a selected organ in vivo
BR9612685A (en) * 1995-11-28 1999-07-20 Genvec Inc Vectors and methods for gene transfer to cells
EP0880596A1 (en) 1995-12-28 1998-12-02 Chiron Corporation Receptor specific chimeric viral surface polypeptides for viral and particle incorporation and internalization in target cells
AU2678097A (en) 1996-04-16 1997-11-07 Immusol Incorporated Targeted viral vectors
WO1998011221A2 (en) 1996-09-13 1998-03-19 Dana-Farber Cancer Institute Car, a novel coxsackievirus and adenovirus receptor
ATE420182T1 (en) 1996-09-25 2009-01-15 Scripps Research Inst PACKAGING CELL LINES USED TO FACILITATE THE DEVELOPMENT OF HIGHLY EFFICIENT ADENOVIRAL VECTORS
US5877011A (en) 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
US5922315A (en) 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins

Also Published As

Publication number Publication date
AU698254B2 (en) 1998-10-29
EP0811069B1 (en) 2008-05-28
US6576456B2 (en) 2003-06-10
US5770442A (en) 1998-06-23
US20020099024A1 (en) 2002-07-25
JPH11500315A (en) 1999-01-12
EP0811069A1 (en) 1997-12-10
ATE397075T1 (en) 2008-06-15
US20030166286A1 (en) 2003-09-04
AU4980496A (en) 1996-09-11
CA2213343C (en) 2009-09-01
WO1996026281A1 (en) 1996-08-29
DE69637545D1 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
CA2213343A1 (en) Chimeric adenoviral fiber protein and methods of using same
WO1996007734A3 (en) Recombinant adenovirus comprising a chimeric penton base protein
ZA963434B (en) Gene therapy using replication competent targeted adenoviral vectors.
AU7264694A (en) Defective adenovirus vectors and use thereof in gene therapy
AU699706C (en) Improved vectors for gene therapy
AU2552795A (en) Safe vectors for gene therapy
EP0633943A4 (en) Gene therapy using targeted viral vectors.
ATE336587T1 (en) ADENOVIRUS VECTOR SYSTEMS AND CELL LINES
EP0710123A4 (en) Adenovirus vectors for gene therapy sponsorship
AU4428496A (en) Direct gene transfer into the ruminant mammary gland
AU5153296A (en) Vectors for gene delivery
AU3972893A (en) Gene therapy using the intestine
CA2161136A1 (en) Adenoviruses having modified fiber proteins
AU4723596A (en) Method for preparing a recombinant adenovirus genome
AU3737297A (en) Bacteriophage-mediated gene therapy
AU3169495A (en) Gene therapy for restenosis using an adenoviral vector
AU7077898A (en) Recombinant vectors derived from adeno-associated virus suitable for gene therapy
AU5297496A (en) Methods of preparation and use of recombinant adenoviral vectors
AUPN631495A0 (en) Vaccine and biological vector(I)
HUP9902150A3 (en) Recombinant adenoviral vectors for human tumour gene therapy
AU4401297A (en) Improved retroviral vectors for gene therapy
CA2278808A1 (en) Methods for cultivating cells and propagating viruses
AU5652396A (en) Glucose-inducible recombinant viral vector
AU4329793A (en) (lactobacillus) expression system using surface protein gene sequences
AU4941096A (en) Self-deleting vectors for gene therapy

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150213